Exelixis, Inc. (Nasdaq:EXEL) and Bristol-Myers Squibb Company (NYSE:BMY) today reported updated phase 2 clinical data which show that XL184 demonstrat ...

Bristol Myers Squibb said Tuesday that its patient support program will now also assist people who lost their job and health insurance due to the COVID-19 pandemic or non-U.S. citizens who are ...

Bristol said 44% to 46% of patients with metastatic melanoma treated with the monoclonal antibody ipilimumab were still alive after one year, while 22% to 24% were still alive after two years ...

Bristol Myers Squibb said on Thursday the injectable form of Opdivo, its blockbuster cancer drug, was found to be non-inferior in a late-stage trial to the approved intravenous form used in ...

As millions lose their jobs—and insurance—Bristol Myers, Eli Lilly expand patient assistance. By Eric Sagonowsky Apr 7, 2020 10:30am. coronavirus COVID-19 drug access drug ... Bristol Myers is ...

Bristol Myers Squibb today announced that ZEPOSIA ® 0.92 mg, a new once-daily oral medication for adults for the treatment of relapsing forms of multiple sclerosis, including clinically isolated ...

Bristol-Myers is already studying a variety of compounds based on the theory of immuno-therapy or the immune system’s own ability to fight cancer.

Bristol Myers Squibb on Thursday said its second-quarter sales fell more than expected and cut its full-year forecasts as two of its top drugs, the blood cancer treatment Revlimid and blood ...

Bristol Myers Squibb said it had not received the complaint and would not comment. "Our condolences go out to the family of Xiaoye Wang," spokeswoman Laura Hortas said. "Bristol-Myers Squibb has ...

Bristol-Myers BMY reported mixed second-quarter results below our projections largely due to lower-than-expected sales of cancer drug Revlimid. Since Revlimid has a short period of exclusivity ...

Q2 revenue at $11.23 bln, misses analysts' estimate 2023 revenue seen falling slightly instead of rising 2023 EPS outlook cut by 60 cents per share July 27 (Reuters) - Bristol Myers Squibb (BMY.N ...

Drugmaker Bristol Myers Squibb said on Thursday its second-quarter sales fell more than expected and cut its full-year forecast as two of its top drugs, blood cancer treatment Revlimid and blood ...